<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499407</url>
  </required_header>
  <id_info>
    <org_study_id>COCTAIL II</org_study_id>
    <nct_id>NCT01499407</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction</brief_title>
  <acronym>COCTAIL II</acronym>
  <official_title>A Randomized Trial to Compare Four Different Intracoronary Modalities to Reduce Thrombus Burden and Improve Microcirculatory Function in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the COCTAIL II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CLI Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CLI Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with ST-elevation myocardial infarction will be randomized, to one of the following:&#xD;
      abciximab infusion with the ClearWay coronary catheter (C), standard abciximab infusion (A),&#xD;
      thrombectomy followed by abciximab infusion with the ClearWay catheter (T+C), or thrombectomy&#xD;
      followed by standard abciximab infusion (T+A). The primary objective is to demonstrate that&#xD;
      abciximab infusion with the ClearWay catheter with or without manual thrombus aspiration&#xD;
      (groups C or T+C) will result in a significant reduction of intra-stent thrombus formations&#xD;
      when compared to intravenous or intracoronary abciximab with or without thrombectomy (groups&#xD;
      A or T+A). The primary endpoint will be the number of cross sections with thrombus area &gt;10%&#xD;
      immediately after stent implantation as assessed with OCT. Additional angiographic, ECG, and&#xD;
      clinical endpoints will be collected and adjudicated. This trial is currently being&#xD;
      registered at ClinicalTrials.gov.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombus area</measure>
    <time_frame>1 week</time_frame>
    <description>The primary endpoint of this trial will be the post-procedural number of cross sections with thrombus area &gt;10% at optical coherence tomography.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Standard abciximab bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ClearWay-infused abciximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrombectomy plus ClearWay-infused abciximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrombectomy plus standard abciximab bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClearWay RX catheter</intervention_name>
    <arm_group_label>ClearWay-infused abciximab</arm_group_label>
    <arm_group_label>Thrombectomy plus ClearWay-infused abciximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <arm_group_label>Standard abciximab bolus</arm_group_label>
    <arm_group_label>Thrombectomy plus standard abciximab bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ischemic symptoms must be present at rest and last for at least 10 minutes,&#xD;
&#xD;
          -  within 6 hours from onset of chest pain,&#xD;
&#xD;
          -  ECG changes will be persistent ST-segment elevation or new-onset left bundle branch&#xD;
             block,&#xD;
&#xD;
          -  cardiac markers can be either in the normal range or elevated (troponin I or T and/or&#xD;
             creatine kinase-myocardial band upper limit of normal for the local laboratory assay),&#xD;
&#xD;
          -  coronary angiogram must be obtained within 6 hours from onset of symptom,&#xD;
&#xD;
          -  the culprit artery must be identified in a native vessel and must show a significant&#xD;
             lesion indicative of local thrombosis with TIMI flow 0-2&#xD;
&#xD;
          -  patients must have signed the informed consent form prior to performance of&#xD;
             trial-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  baseline TIMI flow 3,&#xD;
&#xD;
          -  tortuosity of coronary vessels that may prevent negotiation of target lesions with the&#xD;
             devices that are required by the protocol,&#xD;
&#xD;
          -  myocardial ischemia precipitated by a condition other than atherosclerotic coronary&#xD;
             artery disease (e.g. arrhythmia, severe anemia, hypoxia, thyrotoxicosis, cocaine,&#xD;
             severe valvular disease or hypotension),&#xD;
&#xD;
          -  use of a fibrinolytic agent within 14 days prior to randomization,&#xD;
&#xD;
          -  use of abciximab or any other glycoprotein IIb/IIIa inhibitor within 30 days prior to&#xD;
             randomization,&#xD;
&#xD;
          -  suspected active internal bleeding or history of hemorrhahagic diathesis,&#xD;
&#xD;
          -  major surgery, biopsy of a parenchymal organ, eye surgery, or serious trauma within 6&#xD;
             weeks prior to randomization,&#xD;
&#xD;
          -  gastrointestinal or genitourinary bleeding of clinical significance within 6 weeks&#xD;
             prior to randomization,&#xD;
&#xD;
          -  history of cerebrovascular accident (CVA) or transient ischemic attack within the&#xD;
             previous 2 years or any CVA with a residual neurological deficit,&#xD;
&#xD;
          -  administration of oral anticoagulants within 7 days prior to randomization unless&#xD;
             prothrombin time ≤1.2 times control (or international normalized ratio ≤1.4),&#xD;
&#xD;
          -  ongoing treatment with oral anticoagulant,&#xD;
&#xD;
          -  known current platelet count less than 100.000 cells/µL,&#xD;
&#xD;
          -  prior known intracranial neoplasm, arteriovenous malformation, aneurysm, or aneurysm&#xD;
             repair,&#xD;
&#xD;
          -  known allergy to abciximab or other murine proteins,&#xD;
&#xD;
          -  known impaired renal function (estimated glomerular filtration rate &lt;60 mL/min),&#xD;
&#xD;
          -  coexistent condition associated with a limited life expectancy (e.g. advanced cancer),&#xD;
&#xD;
          -  participation in any phase of another clinical research trial involving the evaluation&#xD;
             of another investigational drug or device within 30 days prior to randomization, known&#xD;
             positive pregnancy test for women of childbearing age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesco Prati, MD</last_name>
    <email>fprati@hsangiovanni.roma.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>A. O. S. Giovanni Addolorata</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CLI Foundation</investigator_affiliation>
    <investigator_full_name>Francesco Prati</investigator_full_name>
    <investigator_title>De.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

